Patents Assigned to GTC Biotherapeutics, Inc.
  • Method for the crystallization of human serum albumin
    Patent number: 7087719
    Abstract: The present invention relates to the purification and production of human albumin from various sources through crystallization and repeated crystallization. Basic features of the invented process include providing specific reaction conditions and precipitating reagents to maximize albumin crystallization. Solubility diagrams are utilized as the basis for process control of the invented method. The current invention specifically controls phosphate concentration, pH and temperature to precisely guide crystallization kinetics and crystal yield.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: August 8, 2006
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Kalevi Visuri, Sinikka Uotila, Scott P. Fulton, Daniel E. Couto
  • Transgenic animals secreting proteins into milk
    Patent number: 7045676
    Abstract: A DNA sequence containing a gene encoding a protein, the gene being under the transcriptional control in the DNA sequence of a mammalian milk protein promoter which does not naturally control the transcription of the gene, such DNA sequence including DNA enabling secretion of the protein.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: May 16, 2006
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Katherine Gordon, Suzanne Groet
  • Treatments using transgenic goat produced antithrombin III
    Patent number: 7019193
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: March 28, 2006
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Paul Ditullio, Harry M. Meade, Edward S. Cole